

Prematurely ended - Statement

EudraCT Number:	2007-006126-10
Full title of the study:	Pilot study to evaluate the efficacy of Efalizumab in patients with cutaneous t-cell lymphoma
Sponsor-ID:	Efalizumab in CTCL
Sponsor:	Charité – Universitätsmedizin Berlin
Product:	Efalizumab
Study Contact:	Prof. Dr. med. Wolfram Sterry Klinik für Dermatologie, Venerologie und Allergologie
Date of early termination:	11.03.2009
Statement:	On behalf of the sponsor, this is confirm that above trial never recruited a patient, due to high health and safety risk for patients. Efalizumab was associated with fatal brain infections and was withdrawn from the market in 2009. Known side effects include bacterial sepsis, viral meningitis, invasive fungal disease and progressive multifocal leukoencephalopathy (PML), a brain infection caused by reactivation of latent JC virus infection.